暂无分享,去创建一个
David Naccache | Marcel Hollenstein | Peter B. Ronne | Peter Y A Ryan | Robert Weil | Ofer Yifrach-Stav
[1] Peter Eaton,et al. Gold nanoparticles for the development of clinical diagnosis methods , 2008, Analytical and bioanalytical chemistry.
[2] S. Nelson,et al. Resolving Individuals Contributing Trace Amounts of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays , 2008, PLoS genetics.
[3] Sook-Kyung Kim,et al. Quantification of Trace-Level DNA by Real-Time Whole Genome Amplification , 2011, PloS one.
[4] C. Mirkin,et al. A gold-nanoparticle-based real-time colorimetric screening method for endonuclease activity and inhibition. , 2007, Angewandte Chemie.
[5] Matthew Osborne,et al. Diagnosing COVID-19: The Disease and Tools for Detection , 2020, ACS nano.
[6] NationalResearchCouncil,et al. A Strategy for Research in Space Biology and Medicine in the New Century , 1998 .
[7] Anne Cambon-Thomsen,et al. The social and ethical issues of post-genomic human biobanks , 2004, Nature Reviews Genetics.
[8] Marco Capocasa,et al. Samples and data accessibility in research biobanks: an explorative survey , 2016, PeerJ.
[9] Timothy Caulfield,et al. Biobanks, consent and claims of consensus , 2012, Nature Methods.
[10] Bradley Malin,et al. Re-identification of DNA through an automated linkage process , 2001, AMIA.
[11] L. Kaminsky,et al. Optimization of Dnase I removal of contaminating DNA from RNA for use in quantitative RNA-PCR. , 1996, BioTechniques.
[12] Christian Drosten,et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.
[13] Z. Tong,et al. Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak , 2020, Journal of medical virology.
[14] M. Calnan,et al. Trust relations in health care--the new agenda. , 2006, European journal of public health.
[15] Duncan Taylor,et al. Interpreting forensic DNA profiling evidence without specifying the number of contributors. , 2014, Forensic science international. Genetics.
[16] 小林 利彦,et al. ビジネスモデル : CentralizedかDecentralizedか(オピニオン) , 2002 .
[17] D. Pang,et al. Colorimetric and visual determination of DNase I activity using gold nanoparticles as an indicator , 2016, Microchimica Acta.
[18] Shinobu Sato,et al. Highly Sensitive Nuclease Assays Based on Chemically Modified DNA or RNA , 2014, Sensors.
[19] Bradley Malin,et al. Determining the identifiability of DNA database entries , 2000, AMIA.
[20] R. Swennen,et al. Irreversible heat inactivation of DNase I without RNA degradation. , 2000, BioTechniques.
[21] Xiaocui Zhu,et al. Simultaneous fluorescence imaging of the activities of DNases and 3' exonucleases in living cells with chimeric oligonucleotide probes. , 2013, Analytical chemistry.
[22] Manfred Kayser,et al. Improving human forensics through advances in genetics, genomics and molecular biology , 2011, Nature Reviews Genetics.
[23] S. Davis,et al. The Unprecedented Stock Market Reaction to COVID-19 , 2020, Review of Asset Pricing Studies.
[24] Yaniv Erlich,et al. Rapid re-identification of human samples using portable DNA sequencing , 2017, eLife.
[25] Cynthia Liu,et al. Assay Techniques and Test Development for COVID-19 Diagnosis , 2020, ACS central science.